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Abstract
Background: Cardiovascular diseases (CVD) are the leading cause of death globally. Cardiac rehabilitation (CR) is
an evidence-based intervention recommended for patients with CVD, to prevent recurrent events and to improve
quality of life. However, despite the proven benefits, only a small percentage of those would benefit from CR
actually receive it worldwide.
This paper by the International Council of Cardiovascular Prevention and Rehabilitation forwards the groundwork
for successful CR advocacy to achieve broader reimbursement, and hence implementation.
Methods: First, the results of the International Council’s survey on national CR reimbursement policies by government
and insurance companies are summarized. Second, a multi-faceted approach to CR advocacy is forwarded. Finally,
as per the advocacy recommendations, the economic impact of CVD and the corresponding benefits of CR and its
cost-effectiveness are summarized. This provides the case for CR reimbursement advocacy.
Results: Thirty-one responses were received, from 25 different countries: 18 (58.1 %) were from high-income
countries, 10 (32.4 %) from upper middle-income, and 3 (9.9 %) from lower middle-income countries. When
asked who reimburses at least some portion of CR services in their country, 19 (61.3 %) reported the government,
17 (54.8 %) reported patients pay out-of-pocket, 16 (51.6 %) reported insurance companies, 12 (38.7 %) reported
that it is shared between the patient and another source, and 7 (22.6 %) reported another source.
Conclusions: Many patients pay out-of-pocket for CR. CR reimbursement around the world is inconsistent and
insufficient. Advocacy campaigns forwarding the CR cause, supported by the relevant literature, enlisting sources
of support in a unified manner with an organized plan, are needed, and must be pursued persistently.
Keywords: Cardiovascular disease, Reimbursement, Cardiac rehabilitation, Insurance
Abbreviations: CR, Cardiac rehabilitation; CVD, Cardiovascular disease; DALYs, Disability-adjusted life years;
ICCPR, International Council for Cardiovascular Prevention and Rehabilitation; SD, Standard deviation;
WHO, World Health Organization
Background
Cardiovascular disease (CVD) is the leading cause of
death globally, [1] and the burden of CVD is growing
[2]. Consequently, CVD accounts for 10 % of disability-
adjusted life years (DALYs) lost worldwide; 10 % of
DALYs lost in low and middle-income countries, and
18 % of DALYs lost in high-income countries [3, 4].
According to the Global Burden of Disease Study, CVD
was the leading cause of disability-adjusted life years lost
in 2010 [4]. In the same year, years lived with disability
due to ischemic heart disease was 8795 for all ages, or
128 per 100,000 [5].
Cardiac rehabilitation (CR) is an outpatient chronic
disease management program for the secondary preven-
tion of CVD. The World Health Organization has de-
fined CR as the “sum of activities required to influence
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favorably the underlying cause of the disease, as well as
the best possible physical, mental and social conditions, so
that they may by their own efforts, preserve or resume
when lost, as normal a place as possible in the society” [6].
The core components of CR include baseline patient as-
sessment, nutritional counseling, risk factor modification,
psychosocial interventions, physical activity counseling
and exercise training [7–13].
The substantive clinical benefits of CR have recently
been summarized [14, 15]. In brief, in high-income
countries, CR is shown to reduce morbidity and mortality
by 25 % [15]. In low and middle-income countries, CR
participation is associated with significant improvements
in lipids, body mass index, blood pressure, as well as
quality of life, and functional capacity [14, 16].
Unfortunately, CR is grossly under-developed around the
globe [17]. While the reasons are multi-factorial, arguably
the chief reason is lack of service reimbursement. Accord-
ingly, the International Council of Cardiovascular Preven-
tion and Rehabilitation (www.globalcardiacrehab.com;
Fig. 1) set out to develop a resource for CR professionals
and associations to advocate for CR reimbursement. This
conceptual paper first describes the scope of the problem
of low use of CR and reimbursement. Results from a sur-
vey undertaken by the International Council regarding CR
reimbursement by government and insurance companies
in various regions of the globe are presented. Second, a 6-
step approach to advocating for CR is provided. The ap-
proach starts with demonstration of the scale of the CVD
problem, and then supporting evidence. Accordingly, the
paper concludes with this needed information, summariz-
ing the economic impact of CVD and the economic bene-
fits of CR, to support CR advocacy efforts.
Significant Gap in cardiac rehabilitation availability and
participation
CR services are scarce. Specifically, CR is available in
only 38.8 % countries worldwide: 68.0 % of high-income,
28.2 % of middle-income and 8.3 % of low-income coun-
tries [17]. Where CR programs are available, it has been
seen that most, if not all countries have insufficient cap-
acity to treat indicated patients [17]. The number of CR
programs per inhabitant (which we refer to as CR density),
is a crude estimate of the number of patients who might
Fig. 1 Member association of the International Council of Cardiovascular Prevention and Rehabilitation
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have access to CR in each country [18]. Based on national
and regional surveys in high-income countries, CR density
ranges from one program per 100,000 to one program per
300,000 inhabitants [19–21]. In middle-income countries,
CR density ranges from 0.9 to 6.4 million inhabitants per
program [19]. No low-income country is known to have
more than 1 CR program [17].
Accordingly, participation in CR is also low [22–24].
For example, the European Action on Secondary Preven-
tion by Intervention to Reduce Events III Survey showed
that only 36.5 % of 8845 indicated patients from 22
European countries (19 of which were high-income)
attended CR [25]. Findings from the European CR In-
ventory Survey revealed that CR enrolment rates >50 %
were seen in only 3 (10.7 %) countries while rates <30 %
were reported in 15 (53.6 %) of the 28 countries [26]. In
the United States, the largest study ever on CR
utilization among 601,099 Medicare beneficiaries eligible
for CR demonstrated that only 12.2 % participated [27].
The international Stabilisation of Atherosclerotic Plaque
by Initiation of Darapladib Therapy trial revealed that
majority of the participants (65 %) had never partici-
pated in CR [28]. The International Council on Cardio-
vascular Prevention and Rehabilitation argues that lack
of CR provision, and hence patient access, is a direct
function of lack of reimbursement.
Reimbursement of cardiac rehabilitation
Coverage of services is tantamount to increasing deliv-
ery. Unfortunately, very little is known about reimburse-
ment for CR services around the globe. In order to
better understand this issue, several authors (AB, FL,
SG) designed an online survey assessing CR reimburse-
ment on behalf of the International Council of Cardio-
vascular Prevention and Rehabilitation. Items assessed
the nature of coverage for CR services by government
and healthcare insurance companies, using a similar ap-
proach as described previously [18, 29]. The survey was
reviewed by experts in the area of CR. Then, it was
emailed to the member organizations of the Inter-
national Council of Cardiovascular Prevention and Re-
habilitation (Fig. 1), who were asked to complete it and
forward it to their CR colleagues from different coun-
tries (i.e., snowball sampling). Respondents were asked
to contact the top 3 health insurers in their country on
the basis of premiums collected and to consult official
government statistics or academic publications to pro-
vide accurate reimbursement data.
This was a cross-sectional study. Thirty-one responses
were received, representing 25 countries (or 34 % of all
83 countries that offer CR globally) [17]. Fifty-eight per-
cent of respondents were from high-income, 32 % upper
middle-income, and 10 % were from lower middle-income
countries. It must be conceded that the generalizability of
responses is unknown, the number of responses was low,
and the source of estimates is unknown (e.g., whether gov-
ernment statistics were accessed and the number of insur-
ance providers successfully contacted). Therefore the
results presented herein, while providing initial valuable
information on CR reimbursement internationally, should
be interpreted with caution. Moreover, results should not
be considered representative of low-income countries.
When asked who reimburses CR in their country
(respondents were asked to check all that apply), 61 %
reported the government, 55 % reported patients pay
out-of-pocket, 52 % reported insurance companies, 39 %
reported that it is shared between the patient and an-
other source, and 23 % reported another source (e.g.,
public hospitals only, subsidized by Heart Foundation,
insurance coverage by some companies only).
Government reimbursement
Government-reimbursed indications for CR were most
often myocardial infarction, coronary artery bypass graft
surgery and percutaneous coronary intervention (all
100 %), followed by heart failure, valve surgery/proce-
dures, and heart transplant (all 87 %), as well as stable
angina (73 %), and rhythm devices (60 %). Respondents
reported that a mean of 32.0 (standard deviation; SD =
12.9) CR sessions were covered by government for each
patient, and that a mean of 91.5 % (SD = 19.2 %) of the
total CR program cost was covered by government (i.e.,
no deductible or out-of-pocket fee). Almost one-fifth of
respondents reported that the government limits the
components of CR covered.
Aspects of CR which were reimbursed most often in-
cluded supervised exercise (93 %), followed by dietary
counselling, mental health/psychological support, smok-
ing cessation, hypertension control and hyperlipidemia
control (all 80 %), education (73 %), weight control
(67 %), and return-to-work/occupational therapy (53 %).
When asked whether the government specified the type
of professional treating the cardiac patient to be eligible
for CR funding, over half responded yes; the type of
professional was most often a cardiologist, nurse or
physiotherapist (each 99 %).
Insurance company reimbursement
Reimbursed indications for CR were synonymous with
those reported with government funding. Respondents
reported that mean of 22.2 (SD = 15.4) sessions were
covered, and that mean of 48.3 % (SD = 50.5 %) of the
total CR program cost was covered by private healthcare
insurance. Where the patient paid some money toward
CR, the average cost was USD$17.5 (SD = 6.9)/session or
USD$345.0 (SD = 38.2)/program. Some respondents
commented that the insurance companies only covered
physical activity and exercise training.
Babu et al. BMC Health Services Research  (2016) 16:471 Page 3 of 9
Advocacy for cardiac rehabilitation
Advocacy is “the act or process of supporting a cause or
proposal” [30]. It involves the art of communication by
an individual or group, often on behalf of others, with
the purpose of supporting an idea or cause. Effective ad-
vocates influence public policy, laws and budgets by
using facts, personal stories, their relationships, the
media, and messaging to educate government officials,
policy-makers and the general public about the import-
ance and the potential impact of the idea or cause they
are supporting. When applied in the healthcare setting,
advocacy is carried out at various levels by a variety of
people—patients, providers, healthcare advocacy groups,
healthcare industry representatives, and others. Health-
care advocacy work is important because the voice of
advocates can help shape and implement important and
beneficial healthcare policies and practices.
Policy-makers face a challenging task of decision-
making while being inundated with a large amount of
data, opinions, and requests. They must maintain a deli-
cate balance between what is best for individuals and
what is best for society. Effective advocates assist policy-
makers in these balancing efforts by helping to clarify
and simplify the complexities of issues that surround a
given idea or cause. Advocates generally speak with a
unique degree of authenticity, as they bring personal
stories and experiences with them that link them to the
cause for which they advocate.
The cause for reimbursement and delivery of CR can
be bolstered by common advocacy pathways. These in-
cluding the upcoming Sustainable Development Goals,
in particular the third proposed goal regarding health,
specifically reducing premature mortality from non-
communicable diseases through prevention and treat-
ment by one-third by 2030, as well as achieving universal
health coverage to promote access to essential medicines
[31, 32]. These current windows of opportunity repre-
sent areas where CR advocacy could find synergy and
hence greater success.
Cardiac rehabilitation-specific advocacy
Despite the large amount of evidence [15, 33, 34] show-
ing the benefits of CR services to eligible patients, advo-
cacy has been challenging. CR services are beneficial, yet
relatively simple and low-cost, when compared to other
services in the field of cardiovascular medicine. Arguably
then, CR services have not generally attracted much
attention from administrators, clinicians, and even
patients, given the “low-tech”, lower budget nature of
CR services.
In the past three decades, CR professionals from vari-
ous countries around the world have been involved as
advocates on behalf of their patients, helping to shape
and implement important healthcare policies for the
provision of CR to eligible patients. Advocacy messaging
has been primarily based on what is in the best interests
of eligible patients—to promote the delivery of CR ser-
vices to the large number of individuals who are eligible
for such services each year.
Components of a successful CR advocacy program are
multi-faceted, and include the following:
a) A just “cause”: The strength of an advocacy
program is dependent largely on the evidence that
CR services provide strong, positive benefits for
individuals and/or society.
b) Publications to support the cause: CR advocacy is
strengthened by research studies and other scholarly
works that have been published in respected,
peer-reviewed scientific publications.
c) Key sources of support: Advocacy is dependent on
key voices of support from the general population,
key national healthcare leaders, key healthcare
organizations, key healthcare policy-makers (i.e.,
someone in an influential position to bring about a
solution or with a personal connection to the issue),
and high visibility public figures who are “champions”
for the cause, giving a face and a sense of personal
impact to the cause.
d) Unified support: Successful CR advocacy depends
on unified support—either for clinical practice or
policy reasons—from leading professional
organizations in the field of cardiology.
e) Organized plan: An organized plan is critically
important to CR advocacy efforts; a plan that
includes goals, strategies and tactics to address
scientific, policy, financial, and communication
needs, among other things.
f ) Persistence: CR advocacy efforts take time and
patience, given the resistance to change that exists at
all levels of the decision-making process, from
patients and providers, to policy-makers and
healthcare leaders.
Communications methods are critically important in
the work of advocacy towards CR. The key to coverage
negotiations is identifying the needs and benefits to the
patient, government and/or insurance companies. By
providing an explanation of the services and benefits of
CR for insured clients, coverage may be considered by
governments and insurance companies. Key points for
communication in a CR advocacy campaign are presented
in Table 1.
In countries where advocacy work has not yet resulted
in insurance coverage policies for CR, healthcare systems
could consider alternative CR models at least for the
short-term, including home-based CR, mobile technology
tools, and other forms of lower-cost delivery models (e.g.,
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outdoor Asociacion Cardiovascular Centrooccidental CR
program in Barquisimeto, Venezuela).
CR professionals have begun advocating for broader
CR delivery and reimbursement. Relenting efforts have
paid off in several countries such as Iran, Qatar, the
United States and United Kingdom. A summary of these
success stories is given in Table 2, and include CR-
supportive funding policy and program initiation in
countries where CR did not exist. For a detailed descrip-
tion, please refer to the online Additional file 1.
To promulgate successful advocacy efforts, organiza-
tions like the American Association of Cardiovascular
and Pulmonary Rehabilitation [35] and World Heart
Federation [36], have provided advocacy tools that can
be found online. Below evidence supporting the need for
CR and its benefits, as per the first 2 CR-specific advo-
cacy components (namely the “cause” and the sources of
information to support it) are provided below.
The need for cardiac rehabilitation
Economic impact of cardiovascular disease
In addition to its’ impact of on mortality and morbidity
as mentioned in the introduction, CVD is also associated
with a significant economic burden. Focusing on only
direct cost (i.e., costs associated with hospital inpatient
care, outpatient physician visits, and medications), CVD
has the highest total costs of any health condition [37].
In the European Union, CVD was estimated to cost
over €106,156,940,0002009 for health care-specific costs
which included five categories: primary care, outpatient
care, emergency, inpatient care, and medications. Non-
health care costs were estimated at €26,963,326,000 due
to mortality, €18,873,665,000 due to morbidity, and
€43,560,202,000 in informal care. Overall, the cost of CVD
to EU was approximately €196 billion annually in 2009
[38] which is a steep increase from €169 in 2003 [39].
A similar picture emerges in North America. In the
United States, CVD also accounts for a large share of
total spending. The average annual cost per person at-
tributable to CVD is $4734 (2005 American dollars)
[40]. By 2030, 40.5 % of the American population is pro-
jected to have some form of CVD, and total direct costs
are projected to reach more than $800 billion in 2008
American dollars (from $273 billion in 2010). The indir-
ect costs due to productivity loss are estimated to in-
crease to $276 billion in 2030.
In low and middle-income countries, the burden of CVD
is of epidemic proportions [41, 42]. Using economic
growth models, which assess the effect of chronic diseases
on national income, the estimated losses because of coron-
ary heart disease, stroke, and diabetes ranged from $20 to
30 million in Ethiopia and Vietnam to almost $1 billion in
larger countries such as India and China [41]. In the sce-
nario with no support to reduce risk of chronic diseases,
an estimated $84 billion of national income (American dol-
lars) will be lost to heart disease, stroke, and diabetes alone
in 23 selected low and middle-income countries between
Table 1 Communication methods for a cardiac rehabilitation
advocacy campaign
Method of communication Description
Key messages This includes important messages
that should be repeated often, and




This includes campaigns towards
policy makers which are well-
controlled and coordinated.
Meetings with policy-makers,
either in private or in public
This provides prime opportunity to
personalize the cause they are
supporting by sharing their
perspective, story, and passion.
Media messaging on the
issue (including social media
and websites)
This includes sharing stories on CR
topics (e.g., patient’s personal story
of triumphs or struggles with heart
disease, new findings of scientific
significance to the field, or expert
opinions about urgent public health
concerns or heart-related illnesses of
public figures) through various
media sources
Abbreviation: CR cardiac rehabilitation
Table 2 Summary of success stories from four countries across
the globe
Country What did they do? What did they achieve?







Ministry of Health that
all components of CR





















guidelines on CR and
formation of standards
for delivery of CR
Created a National
Commissioning Guide

















indications for CR referral
State health plans to
cover essential health
benefits related to CR
Abbreviations: CR cardiac rehabilitation, AACVPR American Association of
Cardiovascular and Pulmonary Rehabilitation, HF heart failure
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2006 and 2015, namely China, India, Russia, Brazil,
Indonesia, Mexico, Turkey, Pakistan, Thailand, Bangladesh,
Ukraine, Egypt, Argentina, Burma, Iran, Poland, South
Africa, Philippines, Colombia, Vietnam, Nigeria, Ethiopia,
and Democratic Republic of the Congo [41].
From an individual’s perspective, CVD poses a great
economic burden on the family and the community. This
is not only due to productivity loss, but also care costs.
Studies indicate that CVD drives approximately 10 % of
affected families into poverty in a low and middle-income
country like India [16]. Moreover, due to disability caused
by CVD, individuals may require assistance with activities
of daily living (which costs money), as well as financial
support if their productivity decreases.
Economic impact of cardiac rehabilitation
Overall, CR has consistently shown to be either cost-saving
or to be cost-effective regardless of the country where it
was examined, the perspective used, the costs included, and
the year when it was analyzed [33]. In fact, European stud-
ies have demonstrated that CR may actually be a cost-
saving intervention [25]. A cost-effectiveness analysis using
pooled data from randomized clinical trials and cohorts
demonstrated that CR would cost $4950 per year of life
saved [26]. Systematic reviews of all the available evidence
show savings of $12,000/CR patient over 5 years, to $9200
per quality-adjusted life year [33]. To put this in perspec-
tive, Table 3 shows cost-effectiveness values for common
treatments and procedures for the secondary prevention of
CVD.
Because CR has been demonstrated to decrease total
mortality, cardiovascular mortality, cardiovascular events,
procedures, and re-hospitalizations, and has shown to im-
prove quality of life, the denominator in the cost-
effectiveness equation is generally as good, or better, than
many other cardiovascular interventions [33, 34, 43, 44]. In
addition to these benefits, CR has also been reported to in-
crease return to work [45]. Those values are presumably
stable across countries and geographic regions, as the
benefit of CR is expected to be similar (as long as the pro-
gram is of good quality and similar to the programs used
in the primary studies). On the contrary, the cost compo-
nent of a cost-effectiveness analysis will vary from country
to country, because the cost of major components of CR
can be significantly different across geographic regions. For
example, major components like the salary for nurses,
Table 3 Cost-effectiveness estimations for different interventions in patients with coronary artery disease
Author (year) Intervention Patient population Estimated savings
Ades et al. (1997) [46] CR versus with other post-MI treatment
interventions
Post MI or revascularization CR was found to result in savings
of 2,130 $/YLS in 1980, which was
projected to be 4,950 $/YLS for
1995
Johanneson et al. (1997) [47] Statins (i.e., Simvastatin) versus no statins Angina or MI Simvastatin use resulted in $3,800
to $27,400 cost per year of life
gained
Cleland et al. (1997) [48] CABG + Medical therapy + aspirin versus
CABG + medical therapy + aspirin + statin
versus medical+aspirin+statin versus
medical + aspirin
Chronic stable angina $36,709, $55,156 and $23,730 per
QALY for each comparison over 5
years
Chan et al. (2007) [49] High intensity versus low intensity statin Acute coronary syndrome,
Chronic coronary disease
From $20,000 to $35,000 if cost
difference of statins is between
$2 and $3.50
From $70,000 to $125,000 if cost
difference of statins is between
$2 and $3.50
Dendale et al. (2008) [50] CR versus no CR Post PCI Reduction in total health care
costs with CR (€4,862/patient
versus €5,498 Euro/patient)
Weinbtraub et al. (2008) [51]a PCI and medical therapy versus Medical
therapy alone
Stable angina $168,000 to $300,000 per QALY
gained with PCI
Wilson et al. (2012) [52] Smoking cessation with varenicline plus
counseling versus counseling only
CVD Savings ranging from €5151 -
€6120 per QALY gained
Smith et al. (2013) [53] Implantable cardiac defibrillator versus no
defibrillator
Primary prevention of sudden death in
patients with left ventricular ejection
fraction <40% (ischemic and non-
ischemic)
€43,993 per QALY gained
compared to no defibrillator
Abbreviations: $/YLS dollars per year of life saved, CVD cardiovascular disease, MI myocardial infarction, PCI percutaneous coronary intervention, QALY, quality-
adjusted life year
aCOURAGE (Clinical Outcomes Utilizing Revascularization and Aggressive druG Evaluations) trial
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physicians, and other healthcare providers are significantly
higher in high-income countries when compared to low
and middle-income countries. Likewise, costs related to
use of physical space and other costs related to the overall
expenses of CR can also be significantly higher in a high-
income country.
Therefore, as the measure of effectiveness is expected
to be similar but costs are expected to be lower in low
and middle-income countries, it is safe to assume that
the estimates of cost-effectiveness for CR will probably
be more favorable in low and middle-income countries.
For example, if the overall cost of CR in a low and
middle-income country is only one-half of the total cost
in a high-income country, the already favorable
estimates for cost-effectiveness may actually become
cost-saving. This suggests that in a low and middle-
income country, not providing CR might actually be
more expensive to payers and to society than providing
CR. This can occur because the lack of a medical inter-
vention (i.e., CR) meant to prevent adverse events and
procedures would lead to major expenses, making the
lack of CR more expensive than offering it itself. We do
concede however that more data in this area is needed.
Conclusions
The need for CR has been established, and the economic
benefits of CR provision have been demonstrated. Given
the evidence of CR benefits for patient health and voca-
tional outcomes, greater provision of these services through
coverage may result in fewer recurrent cardiac events and
associated hospitalizations, fewer revascularization proce-
dures, as well as greater return-to-work and productivity.
Given that CR is cost-effective, greater provision of such
programs may be of significant economic benefit to govern-
ment, insurance companies, the private sector and
individuals.
It is imperative to advocate for reimbursement of CR ser-
vices so that availability and affordability for patients will
be greatly increased. An ancillary consequence will be that
healthcare providers will be motivated to train and work in
the field of CR, which will also enable greater implementa-
tion. It is incumbent upon CR associations to advocate for
CR coverage, using the strategies forwarded herein.
Additional file
Additional file 1: Success stories. (DOCX 23 kb)
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